Thus, hypothetically, even though the upregulation of PD-L1 by polyphenols in cancer could promote disease progression, agents capable of upregulating PD-L1 expression in tumor cells could sensitize cancer cells for an improved clinical response to PD-L1 immune checkpoint blockade therapy. The gene discussed is CD274; the disease is neoplasm.